Hengrui and Braveheart Bio present 52-week data for HRS/BHB-1893 in HCM study
Braveheart and Hengrui presented clinical data at AHA Scientific Sessions 2026 showing that HRS/BHB-1893 significantly improved exercise capacity and reduced LVOT gradients, a development that supports the initiation of the company's planned clinical development in China.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed